Literatura académica sobre el tema "Vaccine"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Vaccine".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Vaccine"
Okanlawon, A. A., S. A. Ameen, R. A. Kadir, H. M. Ambali, Y. A. Baba, O. M. Azeez y A. A. Owoade. "In vitro assessment of the potency of some Newcastle disease vaccine brands in Ibadan, Nigeria". African Journal of Clinical and Experimental Microbiology 21, n.º 4 (25 de agosto de 2020): 328–32. http://dx.doi.org/10.4314/ajcem.v21i4.9.
Texto completoGetova-Kolarova, Violeta, Albena Zlatareva y Ivo Kumanov. "Exploring the nexus of trust, information sources, and vaccination intent: a study of HPV awareness and general practitioner influence". Pharmacia 71 (7 de junio de 2024): 1–6. http://dx.doi.org/10.3897/pharmacia.71.e122666.
Texto completoElizondo-Alzola, Usue, Mireia G. Carrasco, Laia Pinós, Camila Andrea Picchio, Cristina Rius y Elia Diez. "Vaccine hesitancy among paediatric nurses: Prevalence and associated factors". PLOS ONE 16, n.º 5 (19 de mayo de 2021): e0251735. http://dx.doi.org/10.1371/journal.pone.0251735.
Texto completoZakhour, Ramia, Hani Tamim, Farah Faytrouni, Maha Makki, Rayan Hojeij y Lama Charafeddine. "Determinants of human papillomavirus vaccine hesitancy among Lebanese parents". PLOS ONE 18, n.º 12 (13 de diciembre de 2023): e0295644. http://dx.doi.org/10.1371/journal.pone.0295644.
Texto completoSilva Santos, Letícia y Leonardo Sokolnik de Oliveira. "Impact of the COVID-19 pandemic over the perception of the population about vaccines". Brazilian Journal of Global Health 1, n.º 2 (27 de febrero de 2021): 24–27. http://dx.doi.org/10.56242/globalhealth;2021;1;2;24-27.
Texto completoMukherjee, Sanjana, Kanika Kalra y Alexandra L. Phelan. "Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries". PLOS Global Public Health 3, n.º 6 (29 de junio de 2023): e0002098. http://dx.doi.org/10.1371/journal.pgph.0002098.
Texto completoTitanji, Vincent P. K. "New approaches to vaccines for endemic and pandemic diseases of Africa with particular focus on building local competencies in Cameroon". Journal of the Cameroon Academy of Sciences 17, n.º 1 (2 de noviembre de 2021): 75–83. http://dx.doi.org/10.4314/jcas.v17i1.6.
Texto completo&NA;. "Anthrax vaccine/smallpox vaccine/other vaccines". Reactions Weekly &NA;, n.º 1208 (junio de 2008): 6–7. http://dx.doi.org/10.2165/00128415-200812080-00018.
Texto completoMarvila Garcia, Érica, Evelyn Lima de Souza, Fernanda Penido Matozinhos, Tércia Moreira Ribeiro da Silva, Eliseu Alves Waldman y Ana Paula Sayuri Sato. "Associated factors with vaccine hesitancy in mothers of children up to two years old in a Brazilian city". PLOS Global Public Health 3, n.º 6 (8 de junio de 2023): e0002026. http://dx.doi.org/10.1371/journal.pgph.0002026.
Texto completoCasiño, Jenny J. y Angelo Mark P. Walag. "Issues and Challenges of, Factors that Affect, and the Primary Influences of Parents’ Decisions to Vaccinate their Adolescents: A Case of a Local National High School in Cagayan de Oro City, Philippines". Canadian Journal of Family and Youth / Le Journal Canadien de Famille et de la Jeunesse 14, n.º 1 (1 de enero de 2022): 147–61. http://dx.doi.org/10.29173/cjfy29752.
Texto completoTesis sobre el tema "Vaccine"
Piquart, François. "Les vaccins recombinants : données actuelles". Paris 5, 1989. http://www.theses.fr/1989PA05P110.
Texto completoDa, Silva Pissarra Joana. "Development of a multi-epitope peptide vaccine against human leishmaniases". Thesis, Montpellier, 2019. http://www.theses.fr/2019MONTT013/document.
Texto completoLeishmaniasis is a vector-borne neglected tropical disease endemic to 98 countries worldwide. Twenty Leishmania species are capable of establishing intracellular infection within human macrophages, causing different clinical presentations. Vaccine development against leishmaniases is supported by evidence of natural immunity against infection, mediated by a dominant cellular Th1 response and production of IFN-γ, IL-2 and TNF-α by polyfunctional TCD4+ and TCD8+ cells, ultimately leading to macrophage activation and parasite killing.Excreted-secreted proteins are important virulence factors present throughout Leishmania life stages and are able to induce durable protection in dogs, a good model for human infection. We aim to develop a second generation vaccine from the Leishmania secretome, with the potential for large scale dissemination in a cost-effective, reproducible approach.The secretome of six main pathogenic species (plus L. tarentolae) was analysed by Mass-Spectrometry and conserved candidate antigens were searched in the complete dataset. A total of 52 vaccine antigen candidates were selected, including 28 previously described vaccine candidates, and an additional 24 new candidates discovered through a reverse vaccinology approach.In silico HLA-I and –II epitope binding prediction analysis was performed on all selected vaccine antigens, with world coverage regarding HLA restriction. To select the best epitopes, an automated R script was developed in-house, according to strict rational criteria. From thousands of potential epitopes, the automated script, in combination with optimal IC50, homology to host and solubility properties, allowed us to select 50 class I and 24 class II epitopes, synthesized as individual peptides. In vitro toxicity assays showed these selected peptides are non-toxic to cells.The peptides’ immunogenicity was evaluated using immunoscreening assays with immune cells from human donors, allowing for the validation of in silico epitope predictions and selection, and the assessment of the peptide’s immunogenicity and prophylactic potential. Healed individuals, which had active infection and received treatment, possess Leishmania-specific memory responses and are resistant to reinfection, being considered the gold standard of protective immunity. On the other hand, the naive population is extremely important to include in the experimental validation step since it is the target population to vaccinate with a prophylactic vaccine. Importantly, a minimum specific T-cell precursor frequency is needed to induce long-lasting memory protective responses. Furthermore, there is also a positive correlation between immunodominant epitopes and a high frequency of specific T-cell precursors. Peptides able to induce Th1 and/or cytotoxic immune responses in both background are promising candidates for a vaccine formulation. Altogether,experimental validation exclusively in human samples will provide us a very strong base for a vaccine formulation and allow to accelerate translation to the field.Results show Leishmania-specific peptides successfully induce IFN-γ production by total PBMC from healed donors, and by specific T cells amplified from the naïve repertoire. Preliminary evidence exists for peptides which are immunogenic in both immune backgrounds (eight HLA-class I 9-mer peptides and five class II 15-mer peptides) which are, for now, the most promising candidates to advance for the multi-epitope peptide design.Through the combination of proteomic analysis and in silico tools, promising peptide candidates were swiftly identified and the secretome was further established as an optimal starting point for vaccine development. The proposed vaccine preclinical development pipeline delivered a rapid selection of immunogenic peptides, providing a powerful approach to fast-track the deployment of an effective pan-specific vaccine against Leishmaniases
Gayet, Rémi. "Impact de la réponse IgA dans une nouvelle stratégie de vaccination muqueuse contre Salmonella et dans la régulation de la réponse adaptative". Thesis, Lyon, 2018. http://www.theses.fr/2018LYSES015/document.
Texto completoThe enterobacteria Salmonella species are divided into several serovars such as Typhimurium, Enteritidis, Typhi and Paratyphi which are the major causative agents of either gastroenteritis or typhoid fever. They are responsible for more than 90 million cases and 400 000 deaths each year. The increase in multi-drug resistant strains requires the implementation of prophylactic mucosal vaccines. Besides, the intestinal environment is characterized by a balance between immune tolerance and inflammatory response tightly regulated by secretory immunoglobulins (Ig) A. Mucosal IgA are mainly dimeric, serum IgA monomeric and two IgA isotypes have been described in humans: IgA1 and IgA2. We firstly explored the functions of the different isotypes and isoforms of human IgA. We pointed out a pro-inflammatory role of IgA2 whereas IgA1 rather oriented the immunity towards an anti-inflammatory response. We have also highlighted both the regulation of IgA receptors expression by IgA and an IgA/CD8 cytotoxic T cells axis. We also designed a multivalent vaccine against Salmonella by coupling two antigens – SseB and OmpC – to secretory Ig. We pointed out solid specific humoral and cellular responses against both these antigens coupled to either IgA or IgM after intra-nasal immunization in mucosal but also systemic compartments. We have also demonstrated the possibility to preserve and increase the antigen immunogenicity with a multivalent vaccine. This thesis thus paves the way for new secretory Ig-vectorized mucosal vaccines. In addition, the immune response could be modulated through the chosen isotype or isoform and the differences in immune activation generated by structural changes in IgA could shed some light on their role in mucosal homeostasis
Grubb, Kimberley L. "A genomic approach to the identification of novel malaria vaccine antigens /". Thesis, McGill University, 2005. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=98715.
Texto completoAtcheson, Erwan. "Prospects for enhancing malaria vaccine efficacy by combining pre-erythrocytic antigens". Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:6506c003-7065-4d48-b049-f5e9136443d5.
Texto completoZaza, Amélie. "Développement de nouvelles approches thérapeutiques dans la lutte contre les infections à arénavius : vaccination et immunothérapie passive". Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1013.
Texto completoThe Arenaviridae family comprises seven viruses responsible for human hemorrhagic fevers. These viruses represent a natural threat to the local populations, healthcare workers and scientists, as well as to the French forces deployed in the regions where these viruses are endemic. This viral threat can also be intentional in case of a bioterrorist attack. Human hemorrhagic fevers caused by arenaviruses are relatively rare and the first symptoms, frequently non-specific, are often confused with more common diseases such as malaria. Therefore, their diagnosis is delayed, which reduces the efficacy of ribavirin, the only etiological treatment currently recommended. ln this context, the development of prophylactic treatments, such as the Candid #1 vaccine targeting the Junin arenavirus, are an interesting alternative. The first strategy developed in this work to produce a vaccine candidate relied on the attenuation of the virus of interest by targeting a key stage of its replication. We chose the egress step, in which the main actor is the Z protein. This work was conducted using the lymphocytic choriomeningitis virus (LCMV). We therefore designed a reverse genetic system, and replaced the Z gene by the fluorescent protein eGFP reporter gene. Surprisingly, during its cellular infection, a progeny was detected in absence of the Z protein trans-complementation although the titer remained very low. ln this infectious model, we further identified late motifs in the nucleoprotein genome, comparable to those known in the Z protein. These NP late motifs seemed to play an essential role in the compensation of the absence of the Z protein. Similar results were observed using two others arenaviruses of medical importance, the Lassa and Machupo viruses, responsible of human hemorrhagic fevers. The strong diminution of the resulting vaccine candidate replication suggests that this strategy would render safe enough BSL-4 viruses to be used as a multivalent vaccine platform in humans. A complementary approach has been studied in this work. ln order to develop an emergency treatment, based on the production of highly purified F(ab')2 equine immunoglobulins, according to the Fab'entech technology. Two preliminary studies were carried out. The first one consisted in the study of the replication of arenaviruses in circulating horse's white blood cells. The second tested the specifications of attenuated viral particles that could be used as an antigen source to produce the F(ab')2 under good manufacturing practices. Another vaccine strategy was developed using the previously described duplication of the LCMV S genomic small segment in order to produce a tri-segmented recombinant virus. This genetic modification, known to attenuate the LCMV virus pathogenicity, allows the expression of two genes of interest. This strategy has been applied onto the South American Machupo virus, responsible for hemorrhagic fevers in Bolivia. A recombinant Machupo virus was designed to express the truncated glycoproteins of the Chapare and Guanarito viruses, two other New World mammarenaviruses responsible of human hemorrhagic fevers. This vaccine candidate was characterized in cell culture, and showed a 50% post-exposure protective effect in the animal model used. Taken together this work led to the development of two vaccine strategies and to the identification of a promising source of antigens to be used to produce highly purified F(ab')2 polyclonal immunoglobulin, which is the first step to the development of an emergency treatment
Pifferi, Carlo. "Design and synthesis of multivalent glycoconjugates for anti-cancer immunotherapy". Thesis, Université Grenoble Alpes (ComUE), 2017. http://www.theses.fr/2017GREAV060/document.
Texto completoCancer is one on the leading causes of death in developed countries; although surgical resection, direct irradiation and cytotoxic chemotherapy represent nowadays the main treatment options for patients suffering with malignancies, their severe side effects paved the way for the rise in popularity of antitumoral immunotherapy. Apart from passive immunotherapy, which is comprised of antibodies or other immune system components that are made outside of the body and has been shown to be associated to potentially life threatening immune reactions, we focused our efforts towards active immunotherapy, which purpose is stimulate the patient immune system to selectively eradicate malignant cells. The identification of tumor-associated carbohydrate antigens (TACAs) on the surface of cancer cells has allowed the development of antigen-specific vaccines. It has been known for over four decades that the majority of human cancers are characterized by aberrant glycosylation. Tumor cells may over-express truncated versions of oligosaccharides, unusual terminal oligosaccharide sequences, or increase sialylation of cell-surface glycolipids and O- and N-linked glycoproteins. A truncated oligosaccharide of a glycoprotein may render a part of the peptide backbone, which is normally shielded by the glycan, more accessible to the immune system. Among the assortment of TACAs we focussed our attention on Tn and TF-antigens, which can be found in membrane-bound glycoproteins like MUC-1, over-expressed in more than 90% of breast carcinomas. Although the design of such immuno-modulators still relies on empiric rules, it is noteworthy important to trigger both humoral and cellular responses, and a memory effect. This challenge can be achieved by combining, within a single molecule, carbohydrate antigen expressed on the surface of tumors (B-cell epitope), peptides capable to stimulate both CD4+ and CD8+ T-cells (T-cell epitopes) and an adjuvant, to gather immune system elements in the injection site and boost the antigen uptake. Previous studies of our research group reported for the first time the synthesis and immunological evaluation of a four-component anticancer vaccine prototype capable of inducing a long-lasting immune response in mice models. In my PhD work we aimed to synthesize TACA-based anticancer vaccine prototypes with improved immunological properties. The principles which guided our design strategies rely on (i) the importance of a high density of carbohydrate epitopes to promote a more effective antigen capture and processing by antigen-presenting cells, and (ii) the evidence of heterogenic expression patterns of TACAs during the course of the disease and among different individuals. Addressing these two aspects would provide a stronger and multifaceted immune response
Dunachie, Susanna Jane. "Malaria vaccines and microarrays : clinical and laboratory evaluation of two vaccine regimens". Thesis, Open University, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.446277.
Texto completoBOEHNER, CONSTANCE WILLIAMS. "FACTORS AFFECTING STD VACCINE ACCEPTANCE IN COLLEGE STUDENTS". University of Cincinnati / OhioLINK, 2002. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1014411621.
Texto completoHughson, M. D. "Micro-scale vaccine bioprocessing of a Japanese Encephalitis Virus vaccine". Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1427445/.
Texto completoLibros sobre el tema "Vaccine"
Temte, Jonathan L., Mona Marin, Karen R. Broder, Dixie E. Snider y Jane F. Seward. Use of combination measles, mumps, rubella, and varicella vaccine: Recommendations of the Advisory Committee on Immunization Practices. Atlanta, GA: Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2010.
Buscar texto completoR, Siber George, Klugman Keith P y Mäkelä P. Helena, eds. Pneumococcal vaccines: The impact of conjugate vaccine. Washington, DC: ASM Press, 2008.
Buscar texto completoWorkshop on Vaccinia Viruses as Vectors for Vaccine Antigens (1984 Chevy Chase). Vaccinia Viruses as vectors for vaccine antigens. Editado por Quinnan Gerald V. New York: Elsevier, 1985.
Buscar texto completoJha, Prabhat. The potential demand for and strategic use of an HIV-1 vaccine in Southern India. Washington, D.C: World Bank, 2003.
Buscar texto completoRobinson, Andrew, Graham H. Farrar y Christopher N. Wiblin. Vaccine Protocols. New Jersey: Humana Press, 1996. http://dx.doi.org/10.1385/0896033341.
Texto completoO'Hagan, Derek T. Vaccine Adjuvants. New Jersey: Humana Press, 2000. http://dx.doi.org/10.1385/1592590837.
Texto completoRobinson, Andrew, Martin P. Cranage y Michael J. Hudson. Vaccine Protocols. New Jersey: Humana Press, 2003. http://dx.doi.org/10.1385/1592593992.
Texto completoname, No. Vaccine protocols. 2a ed. Totowa, NJ: Humana Press, 2003.
Buscar texto completoThomas, Sunil, ed. Vaccine Design. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1888-2.
Texto completoThomas, Sunil, ed. Vaccine Design. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1884-4.
Texto completoCapítulos de libros sobre el tema "Vaccine"
Wu, Chung-Yi y Chi-Huey Wong. "Vaccines Vaccine". En Glycoscience: Biology and Medicine, 1529–36. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54841-6_198.
Texto completode Carvalho Clímaco, Marianna, Lucas Kraemer y Ricardo Toshio Fujiwara. "Vaccine Development for Human Leishmaniasis". En Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 307–26. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_14.
Texto completoJain, Ananya y Shilpa Sharma. "Nanotechnology in COVID-19 Vaccines". En Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022), 14–26. Dordrecht: Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_3.
Texto completoPathak, Drishya y A. Philo Magdalene. "COVID-19 Vaccine Development and Administration in India". En Health Dimensions of COVID-19 in India and Beyond, 129–54. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7385-6_7.
Texto completoNahler, Gerhard. "vaccine". En Dictionary of Pharmaceutical Medicine, 188. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_1438.
Texto completoTakahashi, Haruko y Kazunari Akiyoshi. "Vaccine". En Encyclopedia of Polymeric Nanomaterials, 1–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-36199-9_224-1.
Texto completoGupta, Varsha, Manjistha Sengupta, Jaya Prakash y Baishnab Charan Tripathy. "Vaccine". En Basic and Applied Aspects of Biotechnology, 305–22. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-0875-7_14.
Texto completoSrinivasan, Ramachandran. "Vaccine". En Encyclopedia of Systems Biology, 2331. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-9863-7_963.
Texto completoTakahashi, Haruko y Kazunari Akiyoshi. "Vaccine". En Encyclopedia of Polymeric Nanomaterials, 2553–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-29648-2_224.
Texto completoGooch, Jan W. "Vaccine". En Encyclopedic Dictionary of Polymers, 931. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_15065.
Texto completoActas de conferencias sobre el tema "Vaccine"
Kumar, Vishnu, Vijay Srinivasan y Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19". En ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.
Texto completoZughaier, Susu. "High Vaccine Coverage is Crucial for Preventing the Spread of Infectious Diseases During Mass Gathering". En Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0138.
Texto completoEraghi, Vida. "Vaccine Development against Paratuberculosis". En Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.i2.
Texto completo"Study of parents' perceptions and opinions on COVID-19 vaccination for their children in Jordan: A cross-sectional". En International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/ylbj6137.
Texto completoKrishnakumar, D. y K. S. Jaganathan. "Development of nasal HPV vaccine formulations". En 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.
Texto completoYin, Jason Dean-Chen. "Vaccine voices in the digital sphere: a multilayer network analysis of online forum discussion in Taiwan". En CARMA 2024 - 6th International Conference on Advanced Research Methods and Analytics. Valencia: Universitat Politècnica de València, 2024. http://dx.doi.org/10.4995/carma2024.2024.17691.
Texto completoAziz, Kareem. "Perspectives, Acceptance, and Hesitancy Among Male and Female Medical Students Regarding Vaccination for COVID-19 in Tishk International University". En 3rd Scientific Conference on Women’s Health. Hawler Medical University, 2022. http://dx.doi.org/10.15218/crewh.2022.04.
Texto completoCamargo, Luana Cristina, Joao Paulo Figueiro Longo, Karen Letycia Rodrigues de Paiva, Marina Mesquita Simões, Thais Bergmann y Victor Carlos Mello da Silva. "Immunotherapy vaccines for triple-negative breast cancer and its influence on the tumor microenvironment". En Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1024.
Texto completoZhu, Richard y Sujata Bhatia. "Optimizing COVID-19 Vaccine Diffusion in Respiratory Mucosa through Stokes-Einstein Modeling". En 2022 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2022. http://dx.doi.org/10.1115/dmd2022-1065.
Texto completo"ATTITUDE TO COVID-19 VACCINATION AMONG PREGNANT WOMEN: THE JORDANIAN EXPERIENCE." En International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/lzes6209.
Texto completoInformes sobre el tema "Vaccine"
Choi, Yoojin, Nathan M. Stall, Antonina Maltsev, Chaim M. Bell, Isaac I. Bogoch, Tal Brosh, Gerald A. Evans et al. Lessons Learned from Israel’s Vaccine Rollout. Ontario COVID-19 Science Advisory Table, febrero de 2021. http://dx.doi.org/10.47326/ocsat.2021.02.09.1.0.
Texto completoByrn, Stephen, Nathaniel Milton y Kari Clase. BIRS Course: RNA Vaccine Manufacture and Assessment of Regulatory Documents for RNA Vaccines. Purdue University, agosto de 2023. http://dx.doi.org/10.5703/1288284317657.
Texto completoPalmer, Guy, Varda Shkap, Wendy Brown y Thea Molad. Control of bovine anaplasmosis: cytokine enhancement of vaccine efficacy. United States Department of Agriculture, marzo de 2007. http://dx.doi.org/10.32747/2007.7695879.bard.
Texto completoSchmidt-Sane, Megan, Elizabeth Benninger, Tabitha Hrynick y Santiago Ripoll. Youth COVID-19 Vaccine Engagement in Cleveland, Ohio, United States. Institute of Development Studies, junio de 2022. http://dx.doi.org/10.19088/ids.2022.040.
Texto completoSchmidt-Sane, Megan, Tabitha Hrynick, Southall Community Alliance SCA, Charlie Forgacz-Cooper y Steve Curtis. Youth COVID-19 Vaccine Engagement in Ealing, London, United Kingdom. Institute of Development Studies, junio de 2022. http://dx.doi.org/10.19088/ids.2022.039.
Texto completoBingamon, Brian Michael. HIV Mosaic Vaccine. Office of Scientific and Technical Information (OSTI), diciembre de 2019. http://dx.doi.org/10.2172/1581247.
Texto completoResearch, Gratis. Intranasal Influenza Vaccine. Gratis Research, marzo de 2021. http://dx.doi.org/10.47496/gr.blog.13.
Texto completoLopez Boo, Florencia, Giuliana Daga y Sofia Madariaga. Combating COVID-19 Vaccine Hesitancy: Behaviorally Informed Campaigns in the Caribbean. Inter-American Development Bank, diciembre de 2022. http://dx.doi.org/10.18235/0004581.
Texto completoBrayton, Kelly A., Varda Shkap, Guy H. Palmer, Wendy C. Brown y Thea Molad. Control of Bovine Anaplasmosis: Protective Capacity of the MSP2 Allelic Repertoire. United States Department of Agriculture, enero de 2014. http://dx.doi.org/10.32747/2014.7699838.bard.
Texto completoAlbornoz, Jorge T. Field Testing of Meningococcal Group B Vaccine and Oral Cholera Vaccine. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1995. http://dx.doi.org/10.21236/ada324898.
Texto completo